SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX

March 08, 2021 2:30 PM EST | Source: Levi & Korsinsky, LLP

New York, New York--(Newsfile Corp. - March 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Athenex, Inc. (NASDAQ: ATNX) ("Athenex") between August 7, 2019 and February 26, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of New York. To get more information go to:

https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=13440&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/76464_920380_logo.jpg

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) that the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Athenex you have until May 3, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/76464

info